Traumatic Brain Injury Therapeutics Market by Nanotechnology, 2015 – 2021

Traumatic Brain Injury Therapeutics Market by
Nanotechnology, 2015 – 2021

P e r s i s t e n c e M a r k e t R e s e a r c h
About Us
Persistence Market Research (PMR) is a market intelligence company, providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking
insight for thousands of decision makers. We have an experienced team of Analysts, Researchers,
and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information indispensable for
businesses to sustain a competitive edge.
Each PMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical,
energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports
provide in-depth analysis and deep segmentation to possible micro levels. With a wider scope and stratified
research methodology, our syndicated reports strive to serve clients and satisfy their overall research
requirement.
Copyright © 2015 Persistence Market Research
All Rights Reserved. This document contains highly confidential information and is the sole property of PMR.
No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of PMR.
Traumatic Brain Injury Therapeutics Market, 2015 - 2021 Page |

P e r s i s t e n c e M a r k e t R e s e a r c h
Report Media Releases
Traumatic Brain Injury Therapeutics Market by Nanotechnology,
2015 – 2021
Traumatic Brain Injury or TBI is sustained from severe or mild damage to the brain tissue from accidents or assaults. In
North America, over 1.7 million people suffer annually from TBI and the consequent medical care costs exceed USD
70 billion. According to WHO, the global incidence for TBI is close to 10 million people annually. Brain tissue has one
of the least self-repair capabilities making it highly vulnerable to injuries and often leading to permanent loss or disability
of motor functions which dramatically reduces the quality of life for any individual. Most neuronal damage occurs
sometime after the injury takes place giving a chance for a therapeutic intervention. The previous intervention with
Glucocorticoids is not considered due to their harmful effects.
Request to view TOC : http://www.persistencemarketresearch.com/toc/5744
A major challenge in developing therapeutics for TBI lie in overcoming the blood-brain barrier while delivering drugs. In
May 2013, DARPA awarded USD 6 million to develop nanotech therapy for combating TBI to a team from University of
California San Diego. Nanotechnology offers chances to overcome this physiological challenge of blood-brain barrier to
deliver therapeutics. These porous silicon nanoparticles can carry a significant drug load through the blood brain barrier
to treat TBI in patients. Other potential treatments include stem cell therapy for CNS trauma and use of apoE-mimetic
compounds. Cognosci, a privately held start-up from North Carolina, U.S. has novel therapeutic compounds in pipeline
for the treatment of TBI which the company expects to launch in coming years with a strategic partnership alliance.
Currently there are two notable clinical trials for gauging the capability of progesterone for traumatic brain injury. The
ProTECT III (progesterone for traumatic brain injury) is currently conducted by the Emory University and is sponsored
by the NIH. The study has recruited patients from 31 TBI clinical centers across the United States. SyNAPSe, initiated
by BHR, a branch of Besins Pharma, in collaboration with the American Brain Injury Consortium (ABIC) and the
European Brain Injury Consortium (EBIC), is another Phase III study investigating the efficacy and safety of
progesterone in patients with severe traumatic brain injuries.
Since there are currently no approved therapeutic products, the sector is teeming with opportunities for new entrants
as well as stalwarts of the pharmaceutical industry. Some of the notable companies developing therapeutics for TBI are
Cognosci, Medicortex, Amarantus BioScience Holdings, Aldagen, NeuroScience Pharmaceuticals and Targacept.
Increasing incidences of TBI due to rising assaults, accidents and military combats over the world are expected to drive
the growth of the market.
Key geographies evaluated in this report are:
North America
o U.S
o Canada
Europe
o France, Germany, Italy, Spain, and the UK
o Eastern Europe
o CIS
APAC
o China
o India
o Japan
o Australia
o Others
Latin America
Traumatic Brain Injury Therapeutics Market, 2015 - 2021 Page |

P e r s i s t e n c e M a r k e t R e s e a r c h
o Argentina
o Brazil
o Others
Request to view Sample Report : http://www.persistencemarketresearch.com/samples/5744
Key features of this report
Drivers, restraints, and challenges shaping the Traumatic Brain Injury Therapeutics market dynamics
Latest innovations and key events in the industry
Analysis of business strategies of the top players
Traumatic Brain Injury Therapeutics market estimates and forecasts(2015 -2021)
For information regarding permissions, contact:
Persistence Market Research
90 Sate Street, Suite 700 Albany, NY 12207
Tel: +1-518-618-1030
Email: sales@persistencemarketresearch.com
Website: http://www.persistencemarketresearch.com/
media@persistencemarketresearch.com
Traumatic Brain Injury Therapeutics Market, 2015 - 2021 Page |